Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States |
| |
| Institution: | 1. Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC;2. Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA;3. Charité Universitätsmedizin Berlin, Urologische Klinik und Hochschulambulanz, Berlin, Germany;4. University of Montréal Hospital Centre, Montréal, Quebec, Canada;5. Division of Urology, Institute of Experimental and Clinical Research, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium;6. Bayer Consumer Care AG, Basel, Switzerland;7. Bayer HealthCare Pharmaceuticals, Whippany, NJ;8. Weill Cornell Department of Medicine, New York-Presbyterian Hospital, New York, NY;9. Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA |
| |
| Abstract: | BackgroundClinical trials have demonstrated the efficacy of several life-prolonging therapies for metastatic castration-resistant prostate cancer (mCRPC); however, real-world data on their use, survival effect, and safety are limited. Using electronic health record data from the Flatiron Health database, we studied real-world treatment patterns and health outcomes in patients with mCRPC.Patients and MethodsWe conducted a retrospective, non-interventional cohort analysis of electronic health record data of patients with confirmed mCRPC between January 2013 and September 2017. The primary objective was to describe real-world treatment patterns, including treatment type, duration, and sequencing. Secondary objectives included describing patient characteristics and clinical outcomes.ResultsOf 2559 patients with mCRPC, 1980 (77%) received at least 1 line of life-prolonging therapy (abiraterone, enzalutamide, docetaxel, cabazitaxel, sipuleucel-T, or radium-223). Of patients receiving first-line therapy, 49% received second-line therapy, and of these, 43% received third-line therapy. Abiraterone/prednisone and enzalutamide accounted for 65% of first-line therapies and 54% of second-line therapies. Docetaxel was the most common third-line therapy (24%). Back-to-back use of abiraterone/prednisone and enzalutamide was common. Radium-223 monotherapy use was 2% in the first-line setting, 3% in the second-line setting, and 8% in the third-line setting. The median overall survival was longer in patients who received life-prolonging therapies (23.7 months; 95% confidence interval: 22.3-25.1 months) than in those who did not (10.1 months; 95% confidence interval: 9.1-11.5 months).ConclusionThese real-world insights on over 2500 patients with mCRPC supplement findings from randomized controlled trials and may help to inform clinical trial design, treatment guidelines, and clinical decision-making. |
| |
| Keywords: | Community practice Database Electronic health record Flatiron Health Retrospective study |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
